Physicians in 2026 grant a pharma rep a visit for one reason above all others: the rep is bringing new or updated clinical information. In a ZoomRx study of 105 US physicians, 94% named this as the entry condition for a productive interaction, ahead of rep preparedness, time efficiency, and every other factor combined. Access itself has changed too. Unannounced visits have nearly disappeared, and scheduling has become a commercial touchpoint in its own right.
That finding comes from "What Earns HCP Time," led by Chitra Alagarsamy, Product Owner for Promotional Effectiveness Tracking at ZoomRx, a life sciences market research consultancy serving pharma and biotech brand teams. For commercial insights, analytics, or commercial effectiveness teams measuring rep visits, it raises a specific question: does your tracking distinguish a visit that cleared this bar from one that didn't?
Unannounced rep visits have effectively exited the physician engagement model. Physicians in ZoomRx's study described four main paths reps use to get time on the calendar:
One oncologist at an academic medical center summarized the shift plainly:
"I only see reps by appointment now. If they can't bring something I haven't heard, I don't extend the visit, and I don't reschedule."
That last part matters as much as the scheduling model itself. Getting on the calendar is the first barrier. What happens once the rep is in the room decides whether there's a second meeting at all.
Once a visit happens, respondents were precise about what makes it worth their time, and what ends it. Asked what earns access to a productive conversation:
Clinical newness sits well above every other factor. Rep preparedness and time efficiency then shape whether the interaction converts into a next appointment, but neither substitutes for it. As one neurologist at an academic medical center put it:
"Only concise, data-driven medical information earns my time. No new data, no meeting."
The same 105 physicians were also asked what destroys trust in a visit. The answers point to specific, avoidable behaviors rather than general fatigue with reps:
Two quotes show how quickly that trust can go. An oncologist described the fastest way to lose them as pivoting "from clinical information to asking how my prescribing has changed since our last meeting," while a neurologist in private practice said being asked to prescribe a specific drug "immediately causes me to lose trust." The visits that earned continued access shared a common thread instead: a neurologist wanted a rep who "knows my patient panel and brings something I haven't heard, a new safety signal," and an oncologist wanted data "specific to my patient type," not generic Phase 3 findings.
Not every new detail carries equal weight. Physicians in the study were specific about which content types actually shift their thinking. Real-world evidence topped the list at 60%, narrowly ahead of clinical trial data at 49%. Patient-specific guidance (21%), safety and tolerability updates (18%), and access or affordability information (16%) trailed well behind both. One academic oncologist described the underlying standard bluntly: "Efficacy data speaks for everything. If there's a survival benefit, it doesn't matter whether it's a new drug or not. Show me the curve."
Real-world evidence edging out clinical trial data, even by a narrow margin, suggests physicians increasingly want proof of how a therapy performs outside the trial population, not just within it. Whether that same distinction between content types shows up consistently in your own promotional effectiveness data is worth checking against ZoomRx's questions to ask before trusting your PET tracker.
Most commercial teams already track rep visits reliably at the level of occurrence: how many calls happened, how often, and with which physicians. That part generally works, and it isn't what's in question here. What's harder to see is whether a visit that cleared the clinical-content bar and one that didn't show up any differently in that same data. A rep who is prepared, respectful of time, and bringing something genuinely new tends to get a second meeting. A rep who isn't, tends not to. On a dashboard that only logs that a call took place, both visits can look identica.
That gap between "a visit happened" and "a visit worked" carries through to what a rep visit produces afterward too, including whether the physician has anything to reference later, and how consistent that experience feels once every other channel reaching the same physician is added in.
The question worth checking against your own tracking: when you pull last quarter's rep visit data, can you tell which interactions actually delivered new clinical information, or does every logged visit carry the same weight regardless of what was said in the room?
This data is drawn from ZoomRx's "What Earns HCP Time" study, surveying 105 US physicians in 2026. The full report is available as an ungated resource below: